Ganapati Hegde is a distinguished Senior Principal Scientist at Bristol Myers Squibb, where he leverages over 15 years of expertise in oncology precision medicine R&D to drive innovative therapeutic solutions. His leadership of the Translational Research Biomarker Group has been pivotal in shaping the company's...
Ganapati Hegde is a distinguished Senior Principal Scientist at Bristol Myers Squibb, where he leverages over 15 years of expertise in oncology precision medicine R&D to drive innovative therapeutic solutions. His leadership of the Translational Research Biomarker Group has been pivotal in shaping the company's approach to biomarker strategies, particularly in the context of early portfolio projects. Under his guidance, a team of five talented scientists has successfully developed comprehensive translational biomarker strategies that encompass indication prioritization, patient segmentation, and the discovery of predictive and pharmacodynamic (PD) biomarkers.
Ganapati's proficiency in model development and target identification has been instrumental in advancing both small molecule therapeutics, such as degraders and inhibitors, as well as large molecule therapeutics, including antibodies and antibody-drug conjugates (ADCs). His hands-on experience in in vitro and in vivo pharmacology has enabled the development of fit-for-purpose prototype assays that are critical for clinical implementation. Moreover, his collaborative approach fosters strong partnerships across various departments, ensuring that the translational research aligns seamlessly with clinical objectives.
In addition to his technical acumen, Ganapati's skills in project management and team leadership have been crucial in navigating complex oncology research landscapes. His ability to present complex scientific concepts clearly and effectively has made him a respected voice in cancer research discussions. With a deep commitment to advancing cancer therapeutics, Ganapati Hegde continues to make significant contributions to the field, driving forward Bristol Myers Squibb's mission to deliver transformative medicines to patients in need.
